To date, it remains a challenge to unveil the molecular and cellular mechanisms by which HNSCC cells develop the de novo and acquired resistance to EGFR-targeted therapies [4, 6]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.